ATE394673T1 - Selbstanordnende moleküle - Google Patents

Selbstanordnende moleküle

Info

Publication number
ATE394673T1
ATE394673T1 AT02781023T AT02781023T ATE394673T1 AT E394673 T1 ATE394673 T1 AT E394673T1 AT 02781023 T AT02781023 T AT 02781023T AT 02781023 T AT02781023 T AT 02781023T AT E394673 T1 ATE394673 T1 AT E394673T1
Authority
AT
Austria
Prior art keywords
self
assembly
target
molecules
single domain
Prior art date
Application number
AT02781023T
Other languages
English (en)
Inventor
C Mackenzie
Jianbing Zhang
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of ATE394673T1 publication Critical patent/ATE394673T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Electroluminescent Light Sources (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02781023T 2001-11-30 2002-11-29 Selbstanordnende moleküle ATE394673T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33409801P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
ATE394673T1 true ATE394673T1 (de) 2008-05-15

Family

ID=23305560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02781023T ATE394673T1 (de) 2001-11-30 2002-11-29 Selbstanordnende moleküle

Country Status (14)

Country Link
US (1) US7655412B2 (de)
EP (1) EP1456651B1 (de)
JP (1) JP4471656B2 (de)
CN (1) CN100335900C (de)
AT (1) ATE394673T1 (de)
AU (1) AU2002349228B2 (de)
BR (1) BR0214621A (de)
CA (1) CA2468583C (de)
DE (1) DE60226486D1 (de)
DK (1) DK1456651T3 (de)
ES (1) ES2306794T3 (de)
MX (1) MXPA04005134A (de)
NZ (1) NZ532838A (de)
WO (1) WO2003046560A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
WO2005014615A2 (en) * 2003-06-25 2005-02-17 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
JP5618453B2 (ja) * 2003-11-28 2014-11-05 ナショナル リサーチ カウンシル オブ カナダ 抗癌抗体およびその使用
EP1737971B1 (de) * 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
EP1943341A4 (de) * 2005-09-27 2010-07-07 Ca Nat Research Council Blut-hirn-schranke-epitope und verwendungen davon
WO2008067591A1 (en) * 2006-12-04 2008-06-12 Innovative Purification Technologies Pty Ltd Protein particles
US8586315B2 (en) * 2007-05-30 2013-11-19 Innovative Purification Technologies Pty Ltd Fluorescent protein particles
CA2740716A1 (en) * 2008-10-14 2010-04-22 Dow Agrosciences Llc Induction of mucosal immune responses by mucosal delivery pentabody complex (mdpc)
CA2740561C (en) 2008-10-14 2021-01-19 National Research Council Of Canada Bsa-specific antibodies
WO2010060216A1 (en) * 2008-11-26 2010-06-03 National Research Council Of Canada Nanoaggregate embedded beads conjugated to single domain antibodies
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
US20100247529A1 (en) * 2009-03-20 2010-09-30 William Patterson Cooperative and dynamic assembly of affinity complexes
US8623369B2 (en) 2010-04-27 2014-01-07 National Research Council Of Canada Anti-ICAM-1 single domain antibody and uses thereof
ES2664989T3 (es) 2010-10-01 2018-04-24 National Research Council Of Canada Anticuerpos ANTI-CEACAM6 y usos de los mismos
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
RU2013139260A (ru) 2011-01-28 2015-03-10 Нэшнл Рисеч Каунсил Оф Канада Конструирование иммуноглобулиновых доменов
DK3150632T3 (en) 2011-06-10 2020-04-27 Canada Minister Nat Defence ANTI-RICIN ANTIBODIES AND APPLICATIONS THEREOF
CN104169304A (zh) 2011-12-20 2014-11-26 阿达拉塔合伙有限公司 作为pcsk9抑制剂的单域抗体
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
MX2015005304A (es) 2012-10-24 2016-04-04 Nat Res Council Canada Anticuerpo contra campylobacter jejuni y usos para los mismos.
EA035517B1 (ru) 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
EP3114142B1 (de) 2014-03-06 2019-06-05 National Research Council of Canada Für insulinähnlichen wachstumsfaktor-1-rezeptor spezifische antikörper und verwendungen davon
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
CN104004093B (zh) * 2014-06-03 2017-01-18 大连理工大学 一种抗人甲状旁腺激素的纳米抗体及其筛选方法和应用
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
CA3001724A1 (en) 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
US10487153B2 (en) 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
MX389765B (es) 2016-07-06 2025-03-20 Nat Res Council Canada Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
US10906973B2 (en) 2016-12-12 2021-02-02 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
CA3051377A1 (en) 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
JP7449092B2 (ja) 2017-01-30 2024-03-13 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門移動化合物及びその使用
EP3784701A4 (de) 2018-04-24 2022-06-08 National Research Council of Canada Die blut-hirn-schranke transmigrierende therapeutische verbindungen und verwendungen davon
EP3853261A4 (de) 2018-09-21 2022-11-09 National Research Council of Canada Intrakörper zur verminderung der fut8-aktivität
US20210324011A1 (en) * 2018-10-25 2021-10-21 University Of Washington Self-assembling protein homo-polymers
US12392777B2 (en) 2019-04-02 2025-08-19 National Research Council Of Canada Antibody variants with pH-dependent antigen binding for selective targeting of solid tumors
CN114099701B (zh) * 2021-11-29 2023-11-10 华中科技大学同济医学院附属协和医院 一种自组装复合多肽及其制备方法和药物
CA3248183A1 (en) 2022-04-14 2023-10-19 The Hospital For Sick Children PFCSP-BASED IMMUNOGENS AND ASSOCIATED COMPOSITION AND METHODS
CN116478303A (zh) * 2023-04-27 2023-07-25 中国人民解放军军事科学院军事医学研究院 可自组装为纳米颗粒的融合蛋白及其在免疫中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5955293A (en) * 1989-10-17 1999-09-21 New England Medical Center Hospitals, Inc. Assays for shiga toxin and shiga-like toxins
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
US5919643A (en) * 1996-06-11 1999-07-06 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
EP0938571B8 (de) * 1996-10-28 2008-07-02 University of Lausanne Verfahren zur oligomerisation von peptiden
US6548066B1 (en) * 1997-05-12 2003-04-15 Aphton Corporation Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
ES2245052T3 (es) * 1997-12-01 2005-12-16 Fang Fang Anticuerpos de recombinacion multivalentes destinados para el tratamiento de infecciones debidas al rinovirus humano (hrv).
US6310043B1 (en) * 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
AU3219300A (en) * 1999-02-01 2000-08-18 Beth Israel Deaconess Medical Center Comp/tsp-1, comp/tsp-2 and other chimeric proteins
AU3798500A (en) * 1999-04-09 2000-11-14 Hsc Research And Development Limited Partnership Verotoxin treatment of lymphomas
WO2001027144A2 (en) 1999-10-08 2001-04-19 Active Biotech Ab Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
WO2001053354A2 (en) * 2000-01-20 2001-07-26 Chiron Corporation Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules

Also Published As

Publication number Publication date
CA2468583C (en) 2012-05-01
NZ532838A (en) 2008-05-30
JP4471656B2 (ja) 2010-06-02
CN1596371A (zh) 2005-03-16
DE60226486D1 (de) 2008-06-19
EP1456651B1 (de) 2008-05-07
CA2468583A1 (en) 2003-06-05
CN100335900C (zh) 2007-09-05
EP1456651A2 (de) 2004-09-15
JP2005510719A (ja) 2005-04-21
MXPA04005134A (es) 2004-08-11
WO2003046560B1 (en) 2003-10-16
WO2003046560A2 (en) 2003-06-05
DK1456651T3 (da) 2008-09-01
US7655412B2 (en) 2010-02-02
AU2002349228B2 (en) 2007-06-14
WO2003046560A3 (en) 2003-09-04
BR0214621A (pt) 2004-10-13
AU2002349228A1 (en) 2003-06-10
ES2306794T3 (es) 2008-11-16
US20060051292A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
DK1456651T3 (da) Selvsamlende molekyler
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA201100527A1 (ru) Биологические продукты
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
DE602006013029D1 (de) Anti-egfr-antikörper
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA200800812A1 (ru) Композиции антитела против cd3
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
CY1118949T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
PT1639011E (pt) Anticorpos (dab) de domínio único peguilados
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
CR9471A (es) Anticuerpos de p-caderina
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
MX2010007357A (es) Puesta de anti-cuerpos en objetivo mediante un dominio de reconocimiento modular.
NZ598770A (en) Monoclonal antibodies
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
MX388698B (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1456651

Country of ref document: EP